Track topics on Twitter Track topics that are important to you
Nodality develops and commercializes the next generation of personal diagnostic tests by characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells. The South San Francisco based company applies proprietary multiparametric Single Cell Network Profiling (SCNP) technology to develop highly predictive biological characterization tests to improve patient management in cancer and autoimmune diseases, the goal of personalized medicine. These tests will permit biologically informed clinical decisions of significant clinical utility. Validation studies for tests to predict success of induction chemotherapy for acute myelogenous leukemia (AML) are underway in collaboration with clinical investigators. In addition to the development of additional clinical tests for AML, SCNP is also being used in the development of new therapeutic agents for patients with other hematologic malignancies, autoimmune diseases, and solid tumors. For more information, please visit www.nodality.com.
Nodality develops and commercializes the next generation of personal diagnostic tests by characterizing cell signaling pathways in defined cellular sub-populations of malig...
We have published hundreds of Nodality, Inc. news stories on BioPortfolio along with dozens of Nodality, Inc. Clinical Trials and PubMed Articles about Nodality, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nodality, Inc. Companies in our database. You can also find out about relevant Nodality, Inc. Drugs and Medications on this site too.
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...